Prevalence and Histopathological Findings of Endometrioid Carcinoma and Associated Risk Factors: A Cross-Sectional Study
Prevalence and Histopathology of Endometrioid Carcinoma
DOI:
https://doi.org/10.54393/pjhs.v5i11.2320Keywords:
Endometrioid Carcinoma, Ovarian Cancer, Parity, Menopausal StatusAbstract
Ovarian cancer ranks as the seventh most frequently diagnosed malignancy among women worldwide. Endometrioid carcinoma, a type of proliferative endometrial tumor, accounts for approximately 15% of epithelial ovarian cancers, making it the third most common subtype. Objective: To investigate the relationship between Endometrioid Carcinoma and potential risk factors, including demographic, reproductive, and lifestyle factors. Methods: A cross-sectional study was conducted at Hayatabad Medical Complex's Department of Pathology from January 1 to December 31, 2023. The study analyzed 139 ovarian tumor specimens confirmed through histopathology. Statistical analysis using SPSS version 26 identified significant associations between variables using Chi-square tests and logistic regression, with a significance level of p < 0.05. Results: A total of 139 ovarian specimens with the patient's mean age (45.34 years) with the highest prevalence of endometrioid carcinoma observed in women aged 40-49 and 60 years and above. The prevalence of endometrioid carcinoma was about 14.4% (n=20). A significant association was identified between parity and endometrioid carcinoma (p-value = <0.001). Menopausal status also showed a significant association, with postmenopausal women having a higher prevalence of endometrioid carcinoma. Logistic regression analysis indicated that age was a significant predictor of endometrioid carcinoma (p-value = 0.028). Conclusions: Significant association between nullipara and premenopausal women with endometrioid carcinoma, emphasizing the importance of considering parity and menopausal status as a risk factor for endometrioid carcinoma.
References
Pragathi Y, Pooja B, AS PA, Nischitha HL, Chandan K, Jain V. AN UPDATED REVIEW ON OVARIAN CANCER. International Journal of Current Innovations in Advanced Research. 2023 Mar: 24-9. doi: 10.47957/ijciar.v6i1.146. DOI: https://doi.org/10.47957/ijciar.v6i1.146
Zhu C, Xu Z, Zhang T, Qian L, Xiao W, Wei H et al. Updates of pathogenesis, diagnostic and therapeutic perspectives for ovarian clear cell carcinoma. Journal of Cancer. 2021 Feb; 12(8): 2295. doi: 10.7150/jca.53395. DOI: https://doi.org/10.7150/jca.53395
Navaneethakrishnan N, Rangaraj RA, Sankaran A. Histopathological Patterns Of Ovarian Tumours-A Retrospective Study In A Tertiary Care Centre. International Journal Academic Medicine Pharmacy. 2024; 6(1): 1563-7.
Goyal D, Agrawal S, Gupta G, Gupta A. Benign ovarian tumours in a tertiary care hospital: A 10 year histopathological study. International Journal of Health Sciences. 2022 May: 9745-50. doi: 10.53730/ijhs.v6nS2.7549. DOI: https://doi.org/10.53730/ijhs.v6nS2.7549
Köbel M and Kang EY. The evolution of ovarian carcinoma subclassification. Cancers. 2022 Jan; 14(2): 416. doi: 10.3390/cancers14020416. DOI: https://doi.org/10.3390/cancers14020416
McSweeney SE and Atri M. Chapter 30 - Malignant Ovarian Masses. In: Fielding JR, Brown DL, Thurmond AS, editors. Gynecologic Imaging. Philadelphia: W.B. Saunders; 2011; 453-69. doi: 10.1016/B978-1-4377-1575-0.10030-1. DOI: https://doi.org/10.1016/B978-1-4377-1575-0.10030-1
Oprescu N, Ionescu CA, Dragan I, Fetecau AC, Said-Moldoveanu AL, Chircu-lescu RA. Adnexal masses in pregnancy: perinatal impact. Romanian Journal of Morphology and Embryology. 2018 Jan; 59(1): 153-8.
Choi JI, Park SB, Han BH, Kim YH, Lee YH, Park HJ et al. Imaging features of complex solid and multicystic ovarian lesions: proposed algorithm for differential diagnosis. Clinical Imaging. 2016 Jan; 40(1): 46-56. doi: 10.1016/j.clinimag.2015.06.008. DOI: https://doi.org/10.1016/j.clinimag.2015.06.008
Wills E, Grenn EE, Orr III WS. Multiple Intraabdominal and Pelvic Cystadenomas From Ovarian Remnant Syndrome. The American Surgeon. 2022 Sep; 88(9): 2218-20. doi: 10.1177/00031348221091962. DOI: https://doi.org/10.1177/00031348221091962
Poon C and Rome R. Malignant extra‐ovarian endometriosis: A case series of ten patients and review of the literature. Australian and New Zealand Journal of Obstetrics and Gynaecology. 2020 Aug; 60(4): 585-91. doi: 10.1111/ajo.13178. DOI: https://doi.org/10.1111/ajo.13178
Zhou L, Yao L, Dai L, Zhu H, Ye X, Wang S et al. Ovarian endometrioid carcinoma and clear cell carcinoma: A 21-year retrospective study. Journal of Ovarian Research. 2021 Dec; 14: 1-2. doi: 10.1186/s13048-021-00804-1. DOI: https://doi.org/10.1186/s13048-021-00804-1
Mei J, Tian H, Huang HS, Hsu CF, Liou Y, Wu N et al. Cellular models of development of ovarian high‐grade serous carcinoma: A review of cell of origin and mechanisms of carcinogenesis. Cell Proliferation. 2021 May; 54(5): e13029. doi: 10.1111/cpr.13029. DOI: https://doi.org/10.1111/cpr.13029
Ahmad Z, Idress R, Fatima S, Uddin N, Ahmed A, Minhas K et al. Commonest cancers in Pakistan-findings and histopathological perspective from a premier surgical pathology center in Pakistan. Asian Pacific Journal of Cancer Prevention. 2016; 17(3): 1061. doi: 10.7314/APJCP.2016.17.3.1061. DOI: https://doi.org/10.7314/APJCP.2016.17.3.1061
Kanwal M, Sarfraz T, Tariq H. Histopathological and Immunohistochemical Evaluation of Malignant Ovarian Tumours. Pakistan Armed Forces Medical Journal. 2024 Feb; 74(1). doi: 10.51253/pafmj.v74i1.5949. DOI: https://doi.org/10.51253/pafmj.v74i1.5949
Falzone L, Scandurra G, Lombardo V, Gattuso G, Lavoro A, Distefano AB et al. A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer. International Journal of Oncology. 2021 Jul; 59(1): 1-4. doi: 10.3892/ijo.2021.5233. DOI: https://doi.org/10.3892/ijo.2021.5233
Ali AT, Al-Ani O, Al-Ani F. Epidemiology and risk factors for ovarian cancer. Menopause Review/Przegląd Menopauzalny. 2023 Jun; 22(2): 93-104. doi: 10.5114/pm.2023.128661. DOI: https://doi.org/10.5114/pm.2023.128661
Ohya A and Fujinaga Y. Magnetic resonance imaging findings of cystic ovarian tumors: major differential diagnoses in five types frequently encountered in daily clinical practice. Japanese Journal of Radiology. 2022 Dec; 40(12): 1213-34. doi: 10.1007/s11604-022-01321-x. DOI: https://doi.org/10.1007/s11604-022-01321-x
Masood M and Singh N. Endometrial carcinoma: changes to classification (WHO 2020). Diagnostic Histopathology. 2021 Dec; 27(12): 493-9. doi: 10.1016/j.mpdhp.2021.09.003. DOI: https://doi.org/10.1016/j.mpdhp.2021.09.003
Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer biology & medicine. 2017 Feb; 14(1): 9-32. doi: 10.20892/j.issn.2095-3941.2016.0084. DOI: https://doi.org/10.20892/j.issn.2095-3941.2016.0084
Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV et al. Ovarian cancer risk factors by histologic subtype: an analysis from the ovarian cancer cohort consortium. Journal of Clinical Oncology. 2016 Aug; 34(24): 2888-98. doi: 10.1200/JCO.2016.66.8178. DOI: https://doi.org/10.1200/JCO.2016.66.8178
Saeed Z, Mushtaq S, Akhtar N, Hassan U. Frequency Of Napsin A Positivity In Ovarian Clear Cell Carcinoma And Serous Carcinoma: Napsin A Positivity in Ovarian Clear Cell Carcinoma. Pakistan Armed Forces Medical Journal. 2018 Aug; 68(4): 723-28.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Pakistan Journal of Health Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments
